ARDX: Ardelyx Pharma Company Value to Net Income

Patents for nephrology drugs and strict FDA oversight drive the asset's dynamics, where the business's price-to-earnings ratio reflects the current trend. Innovative production in the US ensures the protection of developments, while a steady cash flow covers all obligations. The -14.20 mark serves as a relevant indicator, helping investors determine fair value boundaries and avoid overpaying for Ardelyx, Inc. (ARDX) shares.

Ardelyx (ARDX): P/E Multiple from 07/04/2022 to 11/13/2026

Analytical breakdowns for Ardelyx, Inc.

- price and consensus price forecast:

Stock Price ardelyx.com|ARDX - Consensus Target

- market capitalization information:

Market Value Ardelyx, Inc.|ARDX - Total Company Value

- balance sheet net asset value indicators:

Book Value per Share Ardelyx|ARDX - Book Capitalization|Market Capitalization to Book Value ardelyx.com|ARDX - Company Total Assets

- company liabilities and liquidity data:

- net income and valuation ratios data:

ARDX - Company Net Income|Expected Net Income Ardelyx, Inc.|ARDX - P/E Multiple|Price to Future Earnings Ratio Ardelyx Inc|ARDX - PEG Multiple|Company Value to EBITDA Ardelyx, Inc.|ARDX - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Ardelyx|ARDX - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months ardelyx.com|ARDX - Net earnings per share growth this year|Projected earnings per share growth rate for next year Ardelyx, Inc.

Summary company analysis:ARDX (ardelyx.com)

The price action of Ardelyx, Inc. (ARDX) reflects market confidence in its nephrology expansion strategy following management's successful navigation of regulatory hurdles. By analyzing the current P/E ratio, an investor assesses the relationship between market capitalization and net income, which helps determine the premium paid for future growth and avoid unjustified risks during price volatility.

Competing companies